Committee Recommends Approval for Dermatitis Treatment Be Extended

Date : 06/28/2019 @ 12:03PM
Source : Dow Jones News
Stock : Regeneron Pharmaceuticals Inc (REGN)
Quote : 369.68  4.05 (1.11%) @ 4:12PM

Committee Recommends Approval for Dermatitis Treatment Be Extended

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more Regeneron Pharmaceuticals Charts.
   By Allison Prang 
 

The European Medicines Agency's Committee for Medicinal Products for Human Use is recommending that approval for an atopic dermatitis treatment from Regeneron Pharmaceuticals Inc. and Sanofi be extended, the companies said Friday.

The committee is recommending that the European Union approval be extended to also include people with moderate-to-severe cases of this type of dermatitis who are systemic therapy candidates and between ages 12 and 17, the companies said.

They said they expect the European Commission's final decision on the treatment's application should come in the coming months.

 

Write to Allison Prang at allison.prang@wsj.com

 

(END) Dow Jones Newswires

June 28, 2019 07:48 ET (11:48 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest REGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.